Physician profile
Angelo A Baccala
NPI 1811019797
$165,849.96
in general payments reported to CMS, 2019-2025
37 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $17K · 2021: $25K · 2022: $19K · 2023: $28K · 2024: $24K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Honoraria: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $11K · Education: $4,250 · Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,831.26 |
| Honoraria | $20,675.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,498.00 |
| Travel and Lodging | $10,688.49 |
| Education | $4,250.00 |
| Food and Beverage | $3,045.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $48,766.05 | 2020-2025 | Prolaris, Genesight, Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $34,411.71 | 2019-2025 | |
| Astellas Pharma US INC | $15,736.77 | 2019-2024 | Xtandi, Myrbetriq, Veozah |
| Distalmotion US | $15,630.66 | 2024-2025 | Dexter L6 Robot |
| Intuitive Surgical, INC. | $14,979.48 | 2019-2025 | |
| Ethicon INC. | $11,436.76 | 2021 | |
| Pfizer INC. | $10,136.34 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $3,637.96 | 2025 | Adstiladrin |
| Edap Technomed INC | $3,020.23 | 2025 | |
| Boston Scientific Corporation | $1,956.81 | 2019-2025 | General - Kidney Stone Disease |
| Genzyme Corporation | $1,788.00 | 2020 | |
| Janssen Biotech, INC. | $903.40 | 2019-2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $451.08 | 2020-2023 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $391.67 | 2020 | |
| Dendreon Pharmaceuticals LLC | $346.46 | 2019-2023 | Provenge |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $262.21 | 2019 | |
| Photocure INC | $235.76 | 2019-2023 | Cysview |
| Medtronic USA, INC. | $199.08 | 2019 | |
| Olympus America INC. | $184.66 | 2021-2023 | Soltive |
| Karl Storz Endoscopy-America | $164.47 | 2019-2023 | Hopkins |
| Medtronic, INC. | $161.03 | 2021-2022 | |
| Allergan, INC. | $157.15 | 2019-2021 | |
| Myovant Sciences INC. | $144.03 | 2021 | |
| Janssen Scientific Affairs, LLC | $133.02 | 2025 | Erleada |
| Blue Earth Diagnostics | $132.66 | 2019-2022 | |
| Urogen Pharma, INC. | $124.31 | 2020-2023 | Jelmyto |
| Tolmar Pharmaceuticals, INC. | $76.11 | 2019-2020 | |
| Elekta, INC. | $70.00 | 2019 | |
| Sumitomo Pharma America, INC. | $37.88 | 2023 | Gemtesa |
| Axonics, INC. | $37.40 | 2021 | |
| Abbvie INC. | $33.71 | 2019-2023 | Botox |
| Travere Therapeutics, INC. | $24.54 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $18.24 | 2019 | |
| Urovant Sciences INC | $17.29 | 2022 | |
| Coloplast Corp | $15.39 | 2024 | |
| Antares Pharma, INC. | $14.25 | 2022 | |
| Metuchen Pharmaceuticals | $13.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Baccala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.